G01N 33/5011
For testing antineoplastic activity
Official title: {for testing antineoplastic activity}
G01N33/5011 (For testing antineoplastic activity) appears on 2,320 US grants and 4,657 published applications in this corpus.
Search patents in G01N- Granted patents
- 2,320
- Published applications
- 4,657
- Assignees
- 1,562
- Inventors
- 7,855
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 9 | 0 |
| 1995 | 11 | 0 |
| 1996 | 17 | 0 |
| 1997 | 31 | 0 |
| 1998 | 45 | 0 |
| 1999 | 60 | 0 |
| 2000 | 36 | 0 |
| 2001 | 44 | 15 |
| 2002 | 57 | 132 |
| 2003 | 61 | 657 |
| 2004 | 35 | 179 |
| 2005 | 48 | 174 |
| 2006 | 82 | 188 |
| 2007 | 110 | 183 |
| 2008 | 117 | 146 |
| 2009 | 72 | 165 |
| 2010 | 81 | 163 |
| 2011 | 85 | 158 |
| 2012 | 76 | 142 |
| 2013 | 87 | 151 |
| 2014 | 87 | 209 |
| 2015 | 96 | 223 |
| 2016 | 113 | 216 |
| 2017 | 118 | 207 |
| 2018 | 113 | 170 |
| 2019 | 98 | 176 |
| 2020 | 97 | 160 |
| 2021 | 78 | 183 |
| 2022 | 71 | 160 |
| 2023 | 62 | 155 |
| 2024 | 63 | 145 |
| 2025 | 68 | 123 |
| 2026 | 71 | 77 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Liquid crystal scaffolds and use thereof for organoid, spheroid, and 3D cellaggregate manufacturing6 Oct 2026US 12,753,393 B2The Regents of the University of California
- Monoclonal antibody drug sensitivity in multiple myeloma patients6 Oct 2026US 12,754,180 B2The Regents of the University of Colorado, a body corporate
- Fas-associated factor 1 (FAF1)-loaded exosomes and use thereof as anti-cancer agent29 Sep 2026US 12,746,271 B2Kainos Medicine, Inc.
- Composition and method for inhibiting BORC complex to treat cancers with NF1 deficiency and dysregulated RAS signaling29 Sep 2026US 12,748,101 B2Trustees of Dartmouth College
- Compositions and methods for treating cancer22 Sep 2026US 12,740,981 B2The Regents of the University of Michigan
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Beta-elemene derivative containing photoaffinity group diazirine, and preparation method and use thereof as photoaffinity molecular probe8 Oct 2026US 2026/0308128 A1Hangzhou Normal University
- Novel bax variant and pharmaceutical composition comprising same8 Oct 2026US 2026/0308215 A1Cha University Industry-Academic Cooperation Foundation
- Compositions and methods for determining the effects of t cell engager8 Oct 2026US 2026/0309708 A1Arbele Limited
- Panras inhibitor antibody-drug conjugates and methods of use thereof1 Oct 2026US 2026/0295067 A1Novartis AG
Most cited
By later US patents
- High throughput screening assay systems in microscale fluidic devices877US 5,942,443 ACaliper Technologies Corp. · 1999
- Patient classification703US 6,763,307 B2Bioseek, Inc. · 2004
- High throughput screening assay systems in microscale fluidic devices692US 6,046,056 ACaliper Technologies Corp. · 2000
- High throughput screening assay systems in microscale fluidic devices353US 6,267,858 B1Caliper Technologies Corp. · 2001
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009